Eukarÿs SAS
www.eukarys.comEukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination. For further information, see www.eukarys.com.
Read moreEukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination. For further information, see www.eukarys.com.
Read moreCountry
City (Headquarters)
Évry
Industry
Employees
1-10
Founded
2010
Social
Employees statistics
View all employeesPotential Decision Makers
President and Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****Special Advisor
Email ****** @****.comPhone (***) ****-****